Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,827 across all filing types
Latest filing 2019-12-09 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
关于控股股东哈药集团增资扩股事宜的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the progress of a capital increase and share expansion by the controlling shareholder of the company, Harbin Pharmaceutical Group Co., Ltd. It details the procedural steps taken, approvals received, and the impact on the company. The text is a formal public announcement about changes in the shareholder structure and capital increase, not a full financial report or detailed financial statements. It does not contain quarterly or annual financial data, nor is it a transcript or presentation. The document is relatively short (2102 characters) and focuses on corporate actions related to capital and shareholder changes. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2019-12-09 Chinese
关于分公司药品通过仿制药一致性评价的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by 哈药集团股份有限公司 regarding a subsidiary's drug passing a generic drug consistency evaluation by the National Medical Products Administration. It details the drug's basic information, market context, and potential impact on the company. The document is short (1088 characters) and serves as an announcement of a regulatory approval and its business implications rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or detailed governance information. It is not a report publication announcement since it does not mention any attached reports or links. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement about product approval and business impact.
2019-10-31 Chinese
中天国富证券有限公司关于哈药集团有限公司要约收购哈药集团股份有限公司之2019年三季度持续督导意见
M&A Activity Classification · 95% confidence The document is titled as a "2019 Q3 Continuous Supervision Opinion" by Zhongtian Guofu Securities Co., Ltd. regarding the tender offer acquisition of Harbin Pharmaceutical Group Co., Ltd. It is a detailed report covering the supervision and compliance status during the third quarter of 2019 related to the acquisition process. The document includes legal references, compliance with securities laws, and detailed commentary on the acquisition progress, commitments, and operational independence of the acquired company. It is not a full annual or quarterly financial report, nor is it a simple announcement or certification. It is a specialized supervisory opinion report related to a tender offer acquisition, which aligns with the category of M&A Activity (TAR) filings that cover merger proposals and takeover bids. The document length (5614 characters) and content confirm it is a substantive report rather than a brief announcement or certification. Therefore, the appropriate classification is TAR (M&A Activity).
2019-10-31 Chinese
2019年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2019 年第三季度报告" which translates to "2019 Third Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on significant changes and events during the quarter. The report is unaudited and covers the period ending September 30, 2019. It includes management's discussion on financial performance, shareholder information, and other comprehensive financial disclosures typical of an interim or quarterly report. The length of the document (15,000 characters) and the presence of substantive financial data confirm it is a full quarterly report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). 9M 2019
2019-10-25 Chinese
八届十一次监事会决议公告
Regulatory Filings Classification · 95% confidence The document is an announcement of the supervisory board's resolution regarding the 2019 third quarter report. It includes the supervisory board's review and approval of the quarterly report, confirming compliance with laws and regulations and the accuracy of the report. The document is relatively short (653 characters) and serves as an official announcement of the supervisory board's opinion on the quarterly report rather than the report itself. Therefore, it is best classified as a Regulatory Filing (RNS) because it does not contain the full quarterly report or detailed financial data but rather the supervisory board's resolution and opinion on it.
2019-10-25 Chinese
八届二十五次董事会决议公告
Regulatory Filings Classification · 95% confidence The document is a board resolution announcement from Harbin Pharmaceutical Group Co., Ltd. It states that the board meeting approved the 2019 third quarter report and refers readers to the full report published on the Shanghai Stock Exchange website. The document itself is short (445 characters) and does not contain the actual financial data or the full report, only an announcement of the board's approval and a reference to the report's location. According to the 'Menu vs Meal' rule, this is an announcement about the report, not the report itself. Therefore, the correct classification is 'Regulatory Filings' (RNS), as it is a regulatory announcement that does not fit other specific categories.
2019-10-25 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.